Real-World Impact of Subcutaneous Long-Acting Injectable Olanzapine Suspension in Adult Patients with Schizophrenia: RADIANCE study 

RADIANCE is a Phase 4, multinational, non-interventional, prospective observational cohort study designed to assess the real-world clinical, patient-reported, and economic outcomes associated with a long-acting injectable formulation of olanzapine (TV-44749*) when used in routine clinical practice. 

The overall objectives of the study are to evaluate effectiveness, safety/tolerability, treatment patterns, healthcare resource utilization and associated costs, and patient treatment experience of TV-44749 when used in real-world settings.

RADIANCE trial sites will include locations in the US and may expand globally.

*TV-44749 is marketed under the brand name WELTRUZA™.